Hansa Biopharma interim report January-March 2024

/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...

Related Keywords

Sweden ,United States ,Ireland ,Stockholm ,France ,United Kingdom ,Belgium ,Germany ,Hansa Biopharma ,Matthew Shaulis ,Evan Ballantyne ,Hitto Kaufmann ,Stephanie Kenney ,Prnewswire Hansa Biopharma ,Klaus Sindahl ,Vp Global Corporate Affairs ,Gain Therapeutics Inc ,Chief Financial ,Chief Financial Officer ,Gain Therapeutics ,Approval Study ,Genethon Crigler Najjar Phase ,Lead Nicer ,Interim Report ,General Meeting ,Half Year Report January ,Securities Markets ,Nasdaq Stockholm ,